Identification of Novel Prognosis-related Genes in the Endometrial Cancer Immune Microenvironment

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2020 Nov 7

PMID 33159014

Citations 14

Authors

Jian Ma

Jing-Kai Zhang

Di Yang

Xiao-Xin Ma

Affiliations

Soon will be listed here.

Abstract

The incidence of endometrial cancer is increasing each year, and treatment effects are poor for patients with advanced and specific subtypes. Exploring immune infiltration-related factors in endometrial cancer can aid in the prognosis of patients and provide new immunotherapy targets. We downloaded immune metagene and functional data of patients with different subtypes of endometrial cancer from The Cancer Genome Atlas database and selected the lymphocyte-specific kinase (LCK) metagene as a representative genetic marker of the immune microenvironment in endometrial cancer. The results showed that LCK metagene expression is related to the prognosis of patients with endometrioid endometrial adenocarcinoma subtypes and highly correlated with the and mutational status. A search for LCK-related modules returned seven independent genetic predictors of survival in patients with endometrial cancer. The TIMER algorithm showed that the expression of these seven genes was positively correlated with the infiltration levels of six types of immune cells. The diagnostic value of these markers was validated using real-time quantitative PCR and immunohistochemical methods. Our results identified CD74, HLA-DRB5, CD52, HLA-DPB1 and HLA-DRB1 as possible valuable genetic markers for the diagnosis and prognosis of endometrial cancer and provided a theoretical basis for immunotherapy targets for its clinical treatment.

Citing Articles

Identification of CAPG as a potential prognostic biomarker associated with immune cell infiltration and ferroptosis in uterine corpus endometrial carcinoma.

Liu J, Zhu W, Xia L, Zhu Q, Mao Y, Shen Y Front Endocrinol (Lausanne). 2024; 15:1452219.

PMID: 39600941 PMC: 11588481. DOI: 10.3389/fendo.2024.1452219.

Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma.

Zhou H, Wang W, Cai Z, Jia Z, Li Y, He W J Nanobiotechnology. 2024; 22(1):353.

PMID: 38902759 PMC: 11191229. DOI: 10.1186/s12951-024-02646-7.

MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma.

Chen D, Zhang R, Huang X, Ji C, Xia W, Qi Y Biomark Res. 2024; 12(1):14.

PMID: 38291499 PMC: 10829320. DOI: 10.1186/s40364-024-00560-6.

Systematic pan-cancer analysis identifies SLC35C1 as an immunological and prognostic biomarker.

Xie M, Wang F, Chen B, Wu Z, Chen C, Xu J Sci Rep. 2023; 13(1):5331.

PMID: 37005450 PMC: 10067962. DOI: 10.1038/s41598-023-32375-0.

Polo-like kinase 1 is related with malignant characteristics and inhibits macrophages infiltration in glioma.

Luo L, Zhang X, Zhen Y, Guo G, Peng D, Wei C Front Immunol. 2023; 13:1058036.

PMID: 36618405 PMC: 9811677. DOI: 10.3389/fimmu.2022.1058036.

References

Baccar A, Ferchichi I, Troudi W, Marrakchi R, Ben Hmida N, Jebini S . CD99 and HLA-II immunostaining in breast cancer tissue and their correlation with lymph node metastasis. Dis Markers. 2013; 34(5):363-71. PMC: 3810233. DOI: 10.3233/DMA-130982. View

Chen W, Li H, Sun K, Zheng R, Zhang S, Zeng H . [Report of Cancer Incidence and Mortality in China, 2014]. Zhonghua Zhong Liu Za Zhi. 2018; 40(1):5-13. DOI: 10.3760/cma.j.issn.0253-3766.2018.01.002. View

Han B, Olsen N, Bottaro A . The CD27-CD70 pathway and pathogenesis of autoimmune disease. Semin Arthritis Rheum. 2015; 45(4):496-501. DOI: 10.1016/j.semarthrit.2015.08.001. View

Safonov A, Jiang T, Bianchini G, Gyorffy B, Karn T, Hatzis C . Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. Cancer Res. 2017; 77(12):3317-3324. DOI: 10.1158/0008-5472.CAN-16-3478. View

Meyn 3rd M, Smithgall T . Small molecule inhibitors of Lck: the search for specificity within a kinase family. Mini Rev Med Chem. 2008; 8(6):628-37. DOI: 10.2174/138955708784534454. View

Gulati P, Ruhl J, Kannan A, Pircher M, Schuberth P, Nytko K . Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice. Clin Cancer Res. 2018; 24(16):3981-3993. DOI: 10.1158/1078-0432.CCR-17-1788. View

Qi J, Chen S, Chiorazzi N, Rader C . An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. Methods. 2018; 154:70-76. DOI: 10.1016/j.ymeth.2018.08.008. View

Yang L, Wang Y, Zheng L, Jia Y, Chen Y, Chen L . Genetic Polymorphisms of TGFB1, TGFBR1, SNAI1 and TWIST1 Are Associated with Endometrial Cancer Susceptibility in Chinese Han Women. PLoS One. 2016; 11(5):e0155270. PMC: 4865208. DOI: 10.1371/journal.pone.0155270. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt S, Ring K . Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol. 2018; 31(8):1282-1290. DOI: 10.1038/s41379-018-0039-1. View

11.

Zhang S, Minaguchi T, Xu C, Qi N, Itagaki H, Shikama A . PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas. BMC Cancer. 2020; 20(1):127. PMC: 7027009. DOI: 10.1186/s12885-020-6545-9. View

12.

Santin A, Bellone S, Buza N, Choi J, Schwartz P, Schlessinger J . Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res. 2016; 22(23):5682-5687. PMC: 5135588. DOI: 10.1158/1078-0432.CCR-16-1031. View

13.

Neri M, Peiretti M, Melis G, Piras B, Vallerino V, Paoletti A . Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother. 2019; 20(16):2019-2032. DOI: 10.1080/14656566.2019.1654996. View

14.

de Jong R, Leffers N, Boezen H, ten Hoor K, van der Zee A, Hollema H . Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009; 114(1):105-10. DOI: 10.1016/j.ygyno.2009.03.022. View

15.

Slomovitz B, Lu K, Johnston T, Coleman R, Munsell M, Broaddus R . A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010; 116(23):5415-9. PMC: 5120730. DOI: 10.1002/cncr.25515. View

16.

Cheung L, Hennessy B, Li J, Yu S, Myers A, Djordjevic B . High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011; 1(2):170-85. PMC: 3187555. DOI: 10.1158/2159-8290.CD-11-0039. View

17.

Mukaida N, Sasaki S, Baba T . CCL4 Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1231:23-32. DOI: 10.1007/978-3-030-36667-4_3. View

18.

Kumar D, Xu M . Microenvironment Cell Contribution to Lymphoma Immunity. Front Oncol. 2018; 8:288. PMC: 6073855. DOI: 10.3389/fonc.2018.00288. View

19.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E . T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009; 11(2):R15. PMC: 2688939. DOI: 10.1186/bcr2234. View

20.

Oda K, Stokoe D, Taketani Y, McCormick F . High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005; 65(23):10669-73. DOI: 10.1158/0008-5472.CAN-05-2620. View